Wikidata

(Q64638274)

English

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

clinical trial

In more languages

Statements

title
A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy (English)
0 references
country
Austria
0 references
Belgium
0 references
Brazil
0 references
Canada
0 references
Denmark
0 references
France
0 references
Germany
0 references
Israel
0 references
Italy
0 references
Netherlands
0 references
Spain
0 references
Switzerland
0 references
United Kingdom
0 references
start time
13 December 2012
0 references
end time
16 February 2016
0 references
number of participants
631
0 references
research intervention
paclitaxel
0 references
carboplatin
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q64638274&oldid=1857824369"